ProKidney is trading 5.64% up now at $1.41, apparently in a trading rebound without a clearly identified company-specific catalyst.
- Shares fell 5.34% on August 14 and 5.07% on August 13.
- The latest identifiable catalyst was the August 10 earnings release, which reported completed Phase 3 enrollment, a $46.4 million net loss, and cash funding operations into mid-2027; coverage noted an adjusted loss exceeding expectations.
- Broader indexes were modestly lower, so market-wide strength does not clearly explain the move.